SXSW: Biden details Moonshot program to battle cancer

Former Vice President Joe Biden spoke Sunday at SXSW about the White House Cancer Moonshot program’s progress in the fight against cancer, and called for innovators in the audience to use their ingenuity to engineer solutions. The Cancer Moonshot program was established in early 2016 to accelerate innovation in the field of cancer research.

Mission Bio Receives Investment from Life Science Angels

Mission Bio, Inc. announced today that it has secured funding from U.S. top ranked angel investment group Life Science Angels in a seed round to commercialize its high throughput single-cell genomics system. Mission Bio is developing a microfluidic, droplet-based platform to enable critical advances in diseases like cancer, where elucidating heterogeneity in cell populations is essential.

Secretive Biotech Unicorn Moderna Unveils Pipeline, Financials

Moderna Therapeutics Inc., one of the best-funded private biotechnology companies in the U.S., unveiled its long-secret research and development pipeline on Monday, including experimental vaccines, cancer treatments and a cardiovascular therapy. The Cambridge, Massachusetts-based startup has about $1.3 billion in cash on hand from investors, pharmaceutical partners and government grants, according to a presentation Monday at the J.P.Morgan Chase & Co.

US cancer deaths down 25 percent since 1991

Winter Weather Advisory issued January 6 at 11:01AM CST expiring January 6 at 5:00PM CST in effect for: Choctaw, Haskell, Latimer, LeFlore, Pittsburg, Pushmataha Winter Weather Advisory issued January 6 at 9:59AM CST expiring January 6 at 6:00PM CST in effect for: McCurtain Hard Freeze Warning issued January 6 at 4:50AM CST expiring January 7 at 9:00AM CST in effect for: McCurtain Fewer Americans are dying from the second biggest killer in the U.S.: cancer. New numbers from the American Cancer Society show from 1991 to 2014, the cancer death rate has dropped by a quarter.

Pluristem Therapeutics And New York Blood Center To Collaborate In…

Pluristem Therapeutics And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy To Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation to fund the research Constitutes a 3rd potential hematologic indication for PLX-R18 HAIFA, Israel, Dec. 27, 2016 — Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced that it will collaborate with the New York Blood Center on preclinical studies of its Placental eXpanded -R18 cells to enhance the efficacy of umbilical cord blood transplantation.

Oncolytics Biotech Inc. Announces 2016 Year-End Results

“Through this process, and with the help of our expanding senior team, we thoughtfully and deliberately put in place a plan that initially contemplates combinations with chemotherapy for late-stage clinical development, but will expand to include targeted immunotherapies over the longer term as we look to leverage the role of the immune system in patient treatment. In the coming months we will specifically define our first registration pathway.